Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P41181 (
collecting duct
)
5,183
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Autosomal recessive polycystic kidney disease (ARPKD) is a common hereditary renal cystic disease in infants and children. By genetic linkage analyses, the gene responsible for this disease, termed polycystic kidney and hepatic disease 1 (PKHD1), was mapped on human chromosome 6p21.1-p12, and has been further localized to a 1-cM genetic interval flanked by the D6S1714/D6S243 (telomeric) and D6S1024 (centromeric) markers. We recently identified a novel gene in this genetic interval from kidney cDNA, using cloning strategies. The gene PKHD1 (PKHD1-tentative) encodes a novel 3396-amino-acid protein with no apparent homology with any known proteins. We named its gene product "tigmin" because it contains multiple TIG domains, which usually are seen in proteins containing immunoglobulin-like folds. PKHD1 encodes an 11.6-kb transcript and is composed of 61 exons spanning an approximately 365-kb genomic region on chromosome 6p12-
p11
.2 adjacent to the marker D6S1714. Northern blot analyses demonstrated that the gene has discrete bands with one peak signal at approximately 11 kb, indicating that PKHD1 is likely to have multiple alternative transcripts. PKHD1 is highly expressed in adult and infant kidneys and weakly expressed in liver in northern blot analysis. This expression pattern parallels the tissue involvement observed in ARPKD. In situ hybridization analysis further revealed that the expression of PKHD1 in the kidney is mainly localized to the epithelial cells of the
collecting duct
, the specific tubular segment involved in cyst formation in ARPKD. These features of PKHD1 make it a strong positional candidate gene for ARPKD.
...
PMID:A novel gene encoding a TIG multiple domain protein is a positional candidate for autosomal recessive polycystic kidney disease. 1207 88
The epithelial Na
+
channel (ENaC) provides for Na
+
absorption in various types of epithelia including the kidney, lung, and colon where ENaC is localized to the apical membrane to enable Na
+
entry into the cell. The degree of Na
+
entry via ENaC largely depends on the number of active channels localized to the cell membrane, and is tightly controlled by interactions with ubiquitin ligases, kinases, and G-proteins. While regulation of ENaC endocytosis has been well-studied, relatively little is understood of the proteins that govern ENaC exocytosis. We hypothesized that the annexin II light chain,
p11
, could participate in the transport of ENaC along the exocytic pathway. Our results demonstrate that all three ENaC channel subunits interacted with
p11
in an
in vitro
binding assay. Furthermore,
p11
was able to immunoprecipitate ENaC in epithelial cells. Quantitative mass spectrometry of affinity-purified ENaC-
p11
complexes recovered several other trafficking proteins including HSP-90 and annexin A6. We also report that
p11
exhibits a robust protein expression in cortical
collecting duct
epithelial cells. However, the expression of
p11
in these cells was not influenced by either short-term or long-term exposure to aldosterone. To determine whether the
p11
interaction affected ENaC function, we measured amiloride sensitive Na
+
currents in
Xenopus
oocytes or mammalian epithelia co-expressing ENaC and
p11
or a siRNA to
p11
. Results from these experiments showed that
p11
significantly augmented ENaC current, whereas knockdown of
p11
decreased current. Further, knockdown of
p11
reduced ENaC cell surface population suggesting
p11
promotes membrane insertion of ENaC. Overall, our findings reveal a novel protein interaction that controls the number of ENaC channels inserted at the membrane via the exocytic pathway.
...
PMID:Annexin II Light Chain p11 Interacts With ENaC to Increase Functional Activity at the Membrane. 3080 70